Trial Profile
A randomized, placebo-controlled, double-blind, dose escalation study to evaluate the efficacy, safety and tolerability of the study drug BT971 in patients with rheumatoid arthritis receiving concomitant Methotrexate.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2013
Price :
$35
*
At a glance
- Drugs Tregalizumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 05 Aug 2011 This trial is recruiting in Hungary and has completed in Bulgaria
- 05 Aug 2011 New trial record